Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Updated INDIGO data reveal that vorasidenib continues to showcase improved efficacy over placebo in patients with IDH1/2-mutated diffuse glioma.

Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse Glioma

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

Tovorafenib Leads to Durable Off-Treatment Responses in Pediatric BRAF-Altered R/R Low-Grade Glioma

Early safety findings from the phase 2b RESTORE study (NCT03862430) of NanO2 plus radiation and temozolomide in newly diagnosed glioblastoma were shared.

NanO2 Plus Radiation/Temozolomide Is Under Exploration in Newly Diagnosed Glioblastoma

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.

Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Zanidatamab scores approval for HER2+ biliary tract cancer, Versamune HPV is under exploration in HPV16+ head and neck squamous cell carcinoma, and more.

The OncFive: Top Oncology Articles for the Week of 11/17


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Hepatocellular Carcinoma (HCC): Recent Updates and Evolving Treatment Paradigms

Videos

Experts review recent updates in the treatment of HCC and discuss how evidence from clinical trials and real-world settings can be applied to clinical practice to improve patient outcomes.

Experts provide an overview of hepatocellular carcinoma, including the risk factors and prognosis.

Overview of Hepatocellular Carcinoma (HCC)

Key opinion leaders review the process of diagnosing HCC, the role of molecular testing, and associated challenges.

Diagnosing Patients With Hepatocellular Carcinoma

The panel explains the Child-Pugh scoring system and how staging and liver function impact treatment decisions for patients with HCC.

Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC

Manish Shah, MD, details the role of locoregional therapy in HCC, and Julio Gutierrez, MD, comments on transplant as a curative option.

Treatment Approaches for Patients With Early-Stage HCC

Experts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.

The Role of Adjuvant Therapy in Patients With Early-Stage HCC

Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.

Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial

Dr Manish Shah reviews data from the HIMALAYA study on front-line systemic therapy in advanced HCC with tremelimumab plus durvalumab.

Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study

Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.

Optimal Sequencing in Patients With Advanced HCC

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.

Safety Profiles of Available Therapies in Advanced HCC

The panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.

The Future of HCC Treatment

R. Katie Kelley, MD, provides an overview of the first-line systemic treatment options for patients with advanced hepatocellular carcinoma.

First-Line Systemic Treatment Options for Patients With Advanced HCC

Dr R. Katie Kelley shares her thoughts on the four-year updated survival and efficacy data from the phase 3 HIMALAYA trial in patients with advanced hepatocellular carcinoma.

Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study

R. Katie Kelley, MD, discusses updated safety data on tremelimumab plus durvalumab for patients with advanced hepatocellular carcinoma.

Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC

Dr R. Katie Kelley explains the design and results of the phase 3 CELESTIAL study investigating single-agent cabozantinib for the treatment of advanced hepatocellular carcinoma.

The CELESTIAL Study: Cabozantinib Monotherapy in Advanced HCC Treatment

R. Katie Kelley, MD, comments on the safety and efficacy data from the retrospective analysis of the CELESTIAL study in advanced hepatocellular carcinoma.

Safety and Efficacy Data From the Retrospective Analysis of the CELESTIAL Study in Advanced HCC

Dr R. Katie Kelley highlights other abstracts presented at World GI 2023 and shares what she looks forward to in the future of advanced hepatocellular carcinoma treatment.

Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC

EP: 1.Overview of Hepatocellular Carcinoma (HCC)

EP: 2.Diagnosing Patients With Hepatocellular Carcinoma

EP: 3.Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC

EP: 4.Treatment Approaches for Patients With Early-Stage HCC

EP: 5.The Role of Adjuvant Therapy in Patients With Early-Stage HCC

EP: 6.Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial

EP: 7.Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study

EP: 8.Optimal Sequencing in Patients With Advanced HCC

EP: 9.Safety Profiles of Available Therapies in Advanced HCC

EP: 10.The Future of HCC Treatment

EP: 11.First-Line Systemic Treatment Options for Patients With Advanced HCC

EP: 12.Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study

EP: 13.Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC

EP: 14.The CELESTIAL Study: Cabozantinib Monotherapy in Advanced HCC Treatment

EP: 15.Safety and Efficacy Data From the Retrospective Analysis of the CELESTIAL Study in Advanced HCC

EP: 16.Future of Advanced HCC Treatment

Latest Conference Coverage